Jubilant Ingrevia Ltd. · NSE:JUBLINGREA
Jubilant Ingrevia — Q2 FY25 Earnings Presentation
31 slides from Jubilant Ingrevia's earnings presentation, October 2024
Slide 1: Investor Presentation
Jubilant Ingrevia Limited Investor Presentation October 2024 1
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Chairmen's Message on Q2'FY25 Financial Results | 1/2
Chairmen’s Message on Q2’FY25 Financial Results | 1/2 “We are pleased to announce a healthy QoQ & YoY growth for the quarter, fueled by the enhanced performance of our Speciality Chemicals and Nutrition & Health Solutions Businesses, as well as the advantages gained from cost‐saving measures impleme
Slide 4: Chairmen's Message on Q2'FY25 Financial Results | 2/2
Chairmen’s Message on Q2’FY25 Financial Results | 2/2 In the Chemical Intermediates Business, QoQ growth was attributed to an increase in volumes of Ethyl Acetate and Acetic Anhydride. However, the YoY performance declined mainly due to lower prices. Agrochemical CDMO Update: We are excited to share
Slide 5: Table of Contents
Table of Contents 0 6 Company Overview 1 1 Growth Roadmap 1 5 Q2’FY25 Highlights 2 2 Business Segments Update 5
Slide 6: Company Overview
Company Overview Our Lighthouse Site Visuals 6 6
Slide 7: Jubilant Ingrevia is the oldest and third largest company in Jubilant Bhartia Group
Jubilant Ingrevia is the oldest and third largest company in Jubilant Bhartia Group 45+ years 2300+ people 3rd largest of legacy in Chemicals space, started with strong leadership team with Company in the Jubilant Group average 25+ years of experience in in 1978 as VAM Organic Chemicals Chemicals sp
Slide 8: Our business is split across 3 business verticals, with global leadership across key product lines
Our business is split across 3 business verticals, with global leadership across our key product lines 41% Revenue Mix 17% Revenue Mix 41% Revenue Mix 57% EBITDA Mix # 16% EBITDA Mix # 27% EBITDA Mix # Specialty Chemicals Nutrition & Health Solutions Chemical Intermediates CDMO (Pharma, Agro, Semi
Slide 9: We serve customers across geographies and sectors
We serve customers across geographies and sectors; increased growth from exports and pharma/cosmetic/nutrition sectors in recent years Our Product Platforms Enable us to serve diverse customer segments and market needs 1• Pyridine Geographical Revenue Split End‐use Industry Revenue Split 2• Diketene
Slide 10: Executive Leadership Team
Executive Leadership Team Deepak Jain Chandan Singh CEO & MD Advisor Energized & experienced leadership team 20 years of industry & 37 years of industry Consulting experience experience Business Leaders Function Leaders Specialty Chemicals Nutrition & Health Chemical Intermediates Ambrish Dixit Ashi
Slide 11: Growth Roadmap (Recap)
Growth Roadmap (Recap) PEER brie fe oie i : G es bene ae
Slide 12: Our new 'Compass' forms the bedrock of our future growth roadmap
Our new ‘Compass’ forms the bedrock of our future growth roadmap PURPOSE VISION Enable a Sustainable World through Leading provider of innovative solutions Chemistry in our core chemistries globally Customer Centricity World-class, Safe Innovation & ESG Leader People Focused Operations Technology Cu
Slide 13: Recap: Future Growth Aspiration to grow 3x - PINNACLE 3.4.5
Recap: Future Growth Aspiration to grow 3x in next 5 years PINNACLE 3.4.5 13
Slide 14: Last one year: good progress in our Pinnacle 345 journey
Last one year: We have already started to make good progress in our Pinnacle 345 journey Creation of a tight budget with 120 Turnaround in Cr+ of Lean/Surge/BE initiatives Specialty and CDMO contract Major events / milestones Nutrition with with Agro Commissioning of DKT plants increase in Innovator
Slide 15: Q2 & H1'FY25 Highlights
gr ceeenly ie a eRe cniinin peat igeaaes HERR EEEMEL 4 ie Bs Bs 2 i. i Bs : i: Be pes & eh 2 8 dese ses aall \ aes REET : He ae bo He ae recent : z : oe : aa i = ales! ae HE He = i : : & H1’FY25 Highlights : ae . a ee tas aa ‘bind Fesbsaticee i i Stor BEES i SE pron ee Hae if iE . : : i ‘ : an ae ae
Slide 16: Market Overview: Q2 & H1'FY25
Market Overview: Q2 & H1’FY25 | Gradual recovery in volumes across segments; prices are still soft in most segments PHARMA • Steady demand with good visibility on volumes across segments; volume growth seen in Pyridine derivatives • Stability in prices across segments; uptick in some areas • Paracet
Slide 17: Key business highlights Q2FY25
Key business highlights Q2FY25: Significant growth in our core categories, higher margins on account of product mix & cost initiatives • Pyridine & Picoline: Significant volume growth on YoY basis; world’s largest and only non‐ Core product platforms continue to Chinese scaled player in Pyridine dri
Slide 18: Financial Results Overview | Q2 & H1'FY25 Consolidated
Financial Results Overview | Q2 & H1’FY25 Consolidated Particulars1 Q2'FY24 Q1'FY25 Q2'FY25 Q‐o‐Q Y‐o‐Y H1'FY24 H1'FY25 Y‐o‐Y Total Revenue 1,020 1,024 1,045 2.0% 2.5% 2,095 2,070 -1.2% Total EBITDA 126 119 135 13.4% 7.0% 251 254 1.1% EBITDA Margin (%) 12% 12% 13% 12% 12% Profit After Tax 57 49 59 2
Slide 19: We are seeing a gradual recovery from the lows of H2'FY24
We are seeing a gradual recovery from the lows of H2’FY24 EBITDA (INR Crs.) EBITDA Margins 135 125 126 119 12.9% 11.6% 12.1% 11.6% 10.8% 9.4% 104 101 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Revenue 1075 1020 966 1074 1024 1045 (INR Crs) 19
Slide 20: Secular YoY and QoQ EBITDA growth across Specialty Chemicals and Nutrition
We continue to see secular YoY and QoQ EBITDA growth across Specialty Chemicals and Nutrition along with margin expansion Specialty Chemicals Nutrition & Health Solutions EBITDA (Rs Cr.) EBITDA (Rs Cr.) Y.o.Y Growth 26% Y.o.Y Growth 29% Q.o.Q Growth 1% Q.o.Q Growth 5% 86 87 24 23 69 19 18% 20% 20% 5
Slide 21: WEF recognises Bharuch facility as a Global Manufacturing Lighthouse
WEF recognises Bharuch facility as a Global Manufacturing Lighthouse Jubilant Ingrevia is now a member of the elite Global Lighthouse Network (GLN) of the World Economic Forum (WEF) Global Lighthouse Network Digital Impact @ Bharuch GLN is a community of 172 Bharuch manufacturing site is designated
Slide 22: Business Segments Overview
Business Segments Overview 22
Slide 23: Specialty Chemicals | Market, Business & Financial Highlights
1 Specialty Chemicals | Market, Business & Financial Highlights MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS Steady demand from the end‐use segment, volumes remain strong; pricing remained Particulars1 Q2'FY24 Q1'FY25 Q2'FY25 Q‐o‐Q Y‐o‐Y H1'FY24 H1'FY25 Y‐o‐Y steady with uptick in select segments 382 431
Slide 24: Nutrition & Health Solutions | Market, Business & Financial Highlights
2 Nutrition & Health Solutions | Market, Business & Financial Highlights MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS Witnessed improved Niacinamide pricing on QoQ basis Particulars1 Q2'FY24 Q1'FY25 Q2'FY25 Q‐o‐Q Y‐o‐Y H1'FY24 H1'FY25 Y‐o‐Y Increased sales volume and gained market Segment Revenue 162 186
Slide 25: Chemical Intermediates | Market, Business & Financial Highlights
3 Chemical Intermediates | Market, Business & Financial Highlights MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS The primary end‐use markets for Paracetamol continued to face challenges Particulars1 Q2'FY24 Q1'FY25 Q2'FY25 Q‐o‐Q Y‐o‐Y H1'FY24 H1'FY25 Y‐o‐Y Modest recovery was observed in the Segment Revenu
Slide 26: Annexures
Annexures 26 26
Slide 27: Annexure I - Income Statement | Consolidated Q2 & H1'FY25
Annexure I ‐ Income Statement | Consolidated – Q2 & H1‘FY25 Particulars1 Q2'FY24 Q1'FY25 Q2'FY25 QoQ YoY H1'FY24 H1'FY25 YoY Revenue from operations a) Sales/Income from operations 1011 1010 1029 2% 2% 2080 2039 ‐2% b) Other operating income 9 14 16 17% 84% 15 30 98% Total revenue from operations 10
Slide 28: Annexure II: Income Statement Segmental - Q2 & H1'FY25
Annexure II: Income Statement Segmental – Q2 & H1’FY25 Particulars1 Q2'FY24 Q1'FY25 Q2'FY25 QoQ (%) YoY (%) H1'FY24 H1'FY25 YoY (%) Total Revenue from Operations 1,020 1,024 1,045 2% 2% 2,095 2,070 (1%) Speciality Chemicals 382 431 433 1% 13% 745 864 16% Nutrition & Health Solutions 162 186 182 (2%)
Slide 29: Annexure III: Debt Position as on 30th September 2024
Annexure III: Debt Position| As on 30th September 2024 Particulars1 30‐Sep‐23 30‐Jun‐24 30‐Sep‐24 Long Term Borrowings 300 450 450 Short Term Borrowings 457 291 263 Total Gross Debt 757 741 713 Cash & Equivalent 56 64 63 Total Net Debt 701 677 650 YoY change ‐7% • The capex for the quarter was Rs 91
Slide 30: Annexure III - Conference Call Details
Annexure III ‐ Conference Call Details Diamond Pass Log‐In Date : October 22nd, 2024 Time : 05:00 pm IST To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link. Pre‐registration: You will receive dial in numbers, p
Slide 31: Thank you for your time
For More Information For Investors: Jubilant Ingrevia Limited is a global integrated Life Science products and Innovative Solutions provider serving Pavleen Taneja Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with customised products and solutions Jubilant Ingrevia Limi